VitroScan provides predictive testing for cancer patients to determine treatment effectiveness beforehand, resulting in better outcomes.

In modern oncology, the capacity to predict responses to cancer treatment is essential. VitroScan offers state‑of‑the‑art predictive assays that enable clinicians and patients to individualize treatment strategies, thereby improving efficacy, reducing adverse events, and enhancing patient outcomes.

By delivering actionable insights early, VitroScan informs rational therapy selection, accelerates development timelines and supports the successful translation of innovative therapies from lab to patient.

The startup integrates precision patient testing with drug development – advancing the fight against cancer one predictive test at a time.